<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>BioPharma</title>
	<atom:link href="https://www.worldpharmatoday.com/biopharma/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.worldpharmatoday.com</link>
	<description>Magazine for the C-level Pharma Executives</description>
	<lastBuildDate>Tue, 21 Jul 2026 13:11:26 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0.2</generator>

<image>
	<url>https://www.worldpharmatoday.com/wp-content/uploads/2025/12/cropped-World-Pharma-Today-fevicon-32x32.jpg</url>
	<title>BioPharma</title>
	<link>https://www.worldpharmatoday.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Formulation Analytics Accelerating Biologic Development</title>
		<link>https://www.worldpharmatoday.com/biopharma/formulation-analytics-accelerating-biologic-development/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 21 Jul 2026 13:11:26 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/formulation-analytics-accelerating-biologic-development/</guid>

					<description><![CDATA[<p>The development of biological drugs is an intricate process that requires a meticulous understanding of the physical and chemical properties of large, complex proteins. Unlike small molecules, biologics are highly sensitive to their environment, and even minor changes in temperature, pH, or mechanical stress can lead to denaturation or aggregation. To manage these risks, the [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/biopharma/formulation-analytics-accelerating-biologic-development/">Formulation Analytics Accelerating Biologic Development</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Combination Product Design Advancing Biologic Delivery</title>
		<link>https://www.worldpharmatoday.com/biopharma/combination-product-design-advancing-biologic-delivery/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 21 Jul 2026 12:47:03 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Featured]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/combination-product-design-advancing-biologic-delivery/</guid>

					<description><![CDATA[<p>The pharmaceutical sector has witnessed a significant shift toward the development of biologics, which now constitute a substantial portion of the global drug pipeline. Unlike small molecules, biologics are typically large, complex proteins that require parenteral administration due to their susceptibility to degradation in the gastrointestinal tract and their inability to cross biological membranes easily. [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/biopharma/combination-product-design-advancing-biologic-delivery/">Combination Product Design Advancing Biologic Delivery</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>CDMO Strategies Powering the Next-Gen Biopharma Surge</title>
		<link>https://www.worldpharmatoday.com/biopharma/cdmo-strategies-powering-the-next-gen-biopharma-surge/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Sat, 27 Jun 2026 07:51:15 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Business & Industry]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/cdmo-strategies-powering-the-next-gen-biopharma-surge/</guid>

					<description><![CDATA[<p>The biopharmaceutical sector is currently navigating an era of unprecedented growth and technological complexity. As the global drug pipeline shifts toward advanced modalities such as cell and gene therapies, bispecific antibodies, and complex mRNA formulations, the demands placed on manufacturing infrastructure have reached a critical point. Many emerging biotech firms and even established pharmaceutical giants [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/biopharma/cdmo-strategies-powering-the-next-gen-biopharma-surge/">CDMO Strategies Powering the Next-Gen Biopharma Surge</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Extracellular Vesicles and the Future of Cell-Free Therapy</title>
		<link>https://www.worldpharmatoday.com/biopharma/extracellular-vesicles-and-the-future-of-cell-free-therapy/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Sat, 27 Jun 2026 07:49:49 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/extracellular-vesicles-and-the-future-of-cell-free-therapy/</guid>

					<description><![CDATA[<p>The transition from living cell therapies to cell free alternatives represents one of the most significant shifts in modern biotechnology. For years, the regenerative medicine sector has relied on the transplantation of whole cells to repair tissues and modulate the immune system. While these approaches have shown clinical efficacy, they are often hindered by complex [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/biopharma/extracellular-vesicles-and-the-future-of-cell-free-therapy/">Extracellular Vesicles and the Future of Cell-Free Therapy</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Cell and Gene Therapy Delivery Challenges Evolving Now</title>
		<link>https://www.worldpharmatoday.com/biopharma/cell-and-gene-therapy-delivery-challenges-evolving-now/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 26 Jun 2026 06:23:54 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/cell-and-gene-therapy-delivery-challenges-evolving-now/</guid>

					<description><![CDATA[<p>We are currently standing at the threshold of a medical revolution, transitioning from a model of managing chronic conditions to one of potentially curing genetic diseases at their foundational level. The promise of advanced therapeutics such as CRISPR-based gene editing and CAR-T cell therapies is immense, offering hope for conditions that were once considered incurable. [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/biopharma/cell-and-gene-therapy-delivery-challenges-evolving-now/">Cell and Gene Therapy Delivery Challenges Evolving Now</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>The Engine of Cell Therapy Success: Why Analytical Development Determines Whether Promising Cell Therapies Reach Patients</title>
		<link>https://www.worldpharmatoday.com/research-insight/the-engine-of-cell-therapy-success-why-analytical-development-determines-whether-promising-cell-therapies-reach-patients/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 12 Jun 2026 09:57:32 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Research Insight]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/the-engine-of-cell-therapy-success-why-analytical-development-determines-whether-promising-cell-therapies-reach-patients/</guid>

					<description><![CDATA[<p>How advanced analytical methods, potency assays, and immune profiling are shaping the future of cancer cell therapies Cell therapies have transformed the treatment landscape for patients with cancer and other serious diseases. Innovations such as CAR-T cell therapies have demonstrated remarkable clinical success, offering new treatment options for patients with limited alternatives. While much of [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/research-insight/the-engine-of-cell-therapy-success-why-analytical-development-determines-whether-promising-cell-therapies-reach-patients/">The Engine of Cell Therapy Success: Why Analytical Development Determines Whether Promising Cell Therapies Reach Patients</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Daewoong and Chime Biologics Partner for Biosimilar Push</title>
		<link>https://www.worldpharmatoday.com/news/daewoong-and-chime-biologics-partner-for-biosimilar-push/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 10 Jun 2026 12:09:36 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<category><![CDATA[Biopharmaceutical Development]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/daewoong-and-chime-biologics-partner-for-biosimilar-push/</guid>

					<description><![CDATA[<p>Chime Biologics and Daewoong Pharmaceutical have entered into a strategic collaboration to develop and manufacture a dupilumab biosimilar candidate referencing Dupixent for global markets. The partnership, announced by VMS Group, combines the development and manufacturing capabilities of Chime Biologics with Daewoong Pharmaceutical’s plans to expand its presence in the international biosimilars sector. Through this initiative, [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/daewoong-and-chime-biologics-partner-for-biosimilar-push/">Daewoong and Chime Biologics Partner for Biosimilar Push</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Global Biopharmaceutical Position</title>
		<link>https://www.worldpharmatoday.com/news/gni-group-to-acquire-ayumi-pharmaceutical-holdings-expanding-its-global-biopharmaceutical-position/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 09 Jun 2026 07:58:55 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Acquisition]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/gni-group-to-acquire-ayumi-pharmaceutical-holdings-expanding-its-global-biopharmaceutical-position/</guid>

					<description><![CDATA[<p>GNI Group Co., Ltd. has announced an agreement to acquire 100% of the shares of Ayumi Pharmaceutical Holdings Co., Ltd. from a group of shareholders led by Blackstone, in a transaction that values Ayumi Pharmaceutical Holdings at approximately ¥44.8 billion. The deal will make Ayumi a wholly owned subsidiary of GNI Group and significantly expands [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/gni-group-to-acquire-ayumi-pharmaceutical-holdings-expanding-its-global-biopharmaceutical-position/">GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Global Biopharmaceutical Position</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Aragen Achieves Daretabart Commercial-scale GMP Production</title>
		<link>https://www.worldpharmatoday.com/press-releases/aragen-achieves-daretabart-commercial-scale-gmp-production/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 03 Jun 2026 11:50:39 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/aragen-achieves-daretabart-commercial-scale-gmp-production/</guid>

					<description><![CDATA[<p>Aragen, a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) services, has announced the successful technology transfer and commercial-scale GMP manufacturing of the first batches of Daretabart, Renaissance Pharma’s lead therapeutic candidate for high-risk neuroblastoma. The milestone was achieved within just nine months, highlighting the efficiency of the collaboration between the two organizations. [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/press-releases/aragen-achieves-daretabart-commercial-scale-gmp-production/">Aragen Achieves Daretabart Commercial-scale GMP Production</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Nestlé and IdB Partner to Bring rCDI Preventive Therapy to Europe</title>
		<link>https://www.worldpharmatoday.com/biopharma/nestle-and-idb-partner-to-bring-rcdi-preventive-therapy-to-europe/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 01 Jun 2026 05:48:10 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Biopharmaceutical Development]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/nestle-and-idb-partner-to-bring-rcdi-preventive-therapy-to-europe/</guid>

					<description><![CDATA[<p>Nestlé Health Science and IdB Holding have officially announced a VOWST licensing agreement to develop and commercialize the oral therapy in Europe, subject to approval by the European Medicines Agency (EMA). This collaboration aims to expand European patient access to therapies preventing recurrent Clostridioides difficile infection, a severe gastrointestinal condition with limited management options. Currently [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/biopharma/nestle-and-idb-partner-to-bring-rcdi-preventive-therapy-to-europe/">Nestlé and IdB Partner to Bring rCDI Preventive Therapy to Europe</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
	</channel>
</rss>
